COCP - Cocrystal Pharma (COCP) - Influenza Trial Continues With New Clinical Trials Planned For COVID-19

Cocrystal Reported 1Q22 With Pipeline Updates. Cocrystal reported a 1Q22 loss of $4.2 million or $(0.04) per share. The company reviewed its recent clinical progress, including its ongoing Phase 1 study of CC-42344 in influenza and plans to initiate two Phase 1 studies of CC-45205 in COVID-19. Cash at the end of 1Q22 was $54.8 million.Influenza programs. Cocrystal reported Phase 1 data from the CC-42344, its oral PB2 inhibitor for pandemic and seasonal influenza A. The first two cohorts of healthy adults receiving escalating doses of 100 mg and 200 mg, reported positive safety and pharmacokinetic data. This Phase 1 dose escalation trial began in March 2022 in Australia, with additional cohorts continuing enrollment. Additional data is expected during 2022. Read More >>